Morgan Stanley raised the firm's price target on West Pharmaceutical to $325 from $315 and keeps an Equal Weight rating on the shares after having hosted members of West's management team for investor meetings this week. The firm "sensed strong conviction in both near- and longer-term execution as top-down catalysts play into the company's strengths," the analyst tells investors.
